Non-Hodgkin Lymphoma

Alexey Danilov, MD, PhD, highlights the importance of re-evaluating sequencing strategies amid a growing arsenal of targeted therapies in DLBCL.

Panelists discuss how individualized treatment plans must consider disease location, drug access, comorbidities, and newer therapies—such as HDAC inhibitors and immune checkpoint inhibitors— while emphasizing the importance of managing expectations and monitoring adverse effects.

Panelists discuss how treatment goals and selection for advanced-stage cutaneous T-cell lymphoma depend on disease compartmentalization, with therapies like brentuximab vedotin and mogamulizumab being used based on specific disease characteristics and toxicity profiles.

Julie M. Vose, MD, MBA, discusses the durability of response to epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma.

The top 5 OncLive videos of the week cover insights in CLL, multiple myeloma, follicular lymphoma, and extrapulmonary neuroendocrine carcinomas.

Tafasitamab combination gets approval in follicular lymphoma, FDA declines to expand label for talazoparib plus enzalutamide in mCRPC, and more.

Jeremy Abramson, MD, discusses the use of glofitamab with gemcitabine and oxaliplatin in patients with relapsed/refractory DLBCL.

Manali Kamdar, MD, discusses evolving treatment paradigms in diffuse large B-cell lymphoma.

Amitkumar Mehta, MD, details the FDA approval of tafasitamab with rituximab and lenalidomide for relapsed/refractory follicular lymphoma.

The FDA approved tafasitamab-cxix plus lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma.

Panelists discuss how careful patient monitoring, education, and expectation management are essential in evaluating the effectiveness of skin-directed therapies, emphasizing routine assessments, treatment adherence, and the need for patience due to varying response times.

Panelists discuss how electron therapy—both spot and total skin electron beam—is used to manage extensive or refractory skin involvement and palliate symptoms in patients with CTCL.

Hematologic oncology experts share the studies they were most excited to see presented at the 2025 EHA Congress.

Bexobrutideg was safe and displayed an ORR of 84.2% in relapsed/refractory Waldenström macroglobulinemia.

Comparable survival outcomes were seen between all 3 FDA-approved CAR T-cell therapies across indications in patients with DLBCL over a 3-year period.

Liso-cel generated deep and durable responses in relapsed/refractory marginal zone lymphoma.

The majority of transplant-eligible patients with relapsed/refractory DLBCL completed treatment with epcoritamab plus R-ICE and proceeded to ASCT.

Further exploration of epcoritamab plus pola-R-CHP in first-line diffuse large B-cell lymphoma is warranted.

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, discusses safety and efficacy findings with JNJ-90014496 in relapsed/refractory large B-cell lymphoma.

Although age did not affect real-world ORR or EFS with axi-cel in LBCL, an age of 65 years or older and cardiac comorbidities correlated with shorter OS.

JNJ’4496 demonstrated an ORR of 100% in patients with relapsed or refractory large B-cell lymphoma who received 1 prior line of treatment.

Saurabh Dahiya, MD, FACP, discusses safety and efficacy data from a study of the CAR T-cell therapy KITE-363 in relapsed/refractory B-cell lymphoma.

Tetiana Skrypets, MD, PhD, discusses next steps for researching the clinical features and treatment outcomes of older patients with PTCL.

The FDA has approved a tablet formulation of zanubrutinib for use in all 5 approved indications of the capsule formulation.

Panelists discuss how multidisciplinary collaboration between dermatologists and oncologists helps optimize personalized treatment plans by integrating skin-directed and systemic therapies.